Name: Summit Therapeutics Inc. (SMMT) Financial Statements
Creator: FinSpry

Summit Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Summit Therapeutics Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.71	1.81	0.86
Cost of Revenue	15.01	0.00	0.00	0.00	0.00
Gross Profit	-15.01	0.00	0.71	1.81	0.86
Operating Expenses
Research & Development	150.78	59.47	52.00	85.35	53.27
Selling, General & Administrative	60.53	30.27	26.74	23.60	19.23
Operating Expenses	211.30	88.74	64.28	87.98	73.37
Operating Income	0.31	-88.74	-72.09	-86.18	-53.19
Other Income/Expense
Interest Income	13.47	10.40	1.51	0.00	0.00
Interest Expense	8.69	-16.46	4.40	0.24	-0.26
Other Income/Expense	-221.63	-0.25	-12.27	-2.17	0.58
Income
Income Before Tax	-221.32	-614.93	-78.78	-88.60	-52.91
Income Tax Expense	0.00	0.00	0.00	0.00	-0.21
Net Income	-221.32	-614.93	-78.78	-88.60	-52.70
Net Income - Continuous Operations	-221.32	-614.96	-78.78	-88.60	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-212.85	-88.54	-71.87	-85.91	-50.65
EBIT	-212.60	-88.74	-74.38	-88.36	-52.66
Depreciation & Amortization	17.15	0.20	0.35	2.46	0.30
Earnings Per Share
Basic EPS	-	-1.00	-	-1.00	-1.00
Diluted EPS	-	-1.00	-	-1.00	-1.00
Basic Shares Outstanding	718.54	619.65	193.34	92.29	69.52
Diluted Shares Outstanding	718.54	619.65	193.34	92.29	69.52